Literature DB >> 20195155

Evaluation of cardiovascular risk predicted by different SCORE equations: the Netherlands as an example.

Ineke van Dis1, Daan Kromhout, Johanna M Geleijnse, Jolanda M A Boer, W M Monique Verschuren.   

Abstract

BACKGROUND: In Europe, for primary prevention of cardiovascular diseases (CVD), the Systematic COronary Risk Evaluation (SCORE) risk charts for high-risk and low-risk regions (SCORE-high and SCORE-low, respectively) are used. For the Dutch 'Clinical Practice Guideline for Cardiovascular Risk Management' an adapted SCORE risk chart (SCORE-NL) was developed in collaboration with the SCORE group. We evaluated these three SCORE equations using Dutch risk factor and mortality data.
DESIGN: Prospective cohort study with 10-year follow-up.
METHODS: Baseline data were collected between 1987 and 1997 in 32 885 persons aged 37.5-62.5 years. Vital status was checked and causes of death were obtained from Statistics Netherlands. On the basis of the level of risk factors, the expected number of CVD deaths was calculated by applying the three SCORE equations and compared with the observed number.
RESULTS: The observed CVD mortality was three-fold higher in men (n=242; 1.6%) than in women (n=83; 0.5%). On the basis of SCORE-NL, 8.5% of the men and 0.8% of the women had a CVD mortality risk of 5% or more. The ratio of the observed-to-expected number of CVD deaths was 0.75 for men and 0.55 for women using SCORE-NL, 0.54 and 0.56 using SCORE-high, and 1.11 and 0.95 using SCORE-low.
CONCLUSION: At the population level, SCORE-low predicts the number of CVD deaths well, whereas both SCORE-NL and SCORE-high overestimate the number of CVD deaths by a factor 1.5-2.

Entities:  

Mesh:

Year:  2010        PMID: 20195155     DOI: 10.1097/HJR.0b013e328337cca2

Source DB:  PubMed          Journal:  Eur J Cardiovasc Prev Rehabil        ISSN: 1741-8267


  20 in total

1.  Harmonization of guidelines for the prevention and treatment of cardiovascular disease: the C-CHANGE Initiative.

Authors:  Sheldon W Tobe; James A Stone; Melissa Brouwers; Onil Bhattacharyya; Kimberly M Walker; Martin Dawes; Jacques Genest; Steven Grover; Gordon Gubitz; David Lau; Andrew Pipe; Peter Selby; Mark S Tremblay; Darren E R Warburton; Richard Ward; Vincent Woo; Lawrence A Leiter; Peter P Liu
Journal:  CMAJ       Date:  2011-09-12       Impact factor: 8.262

2.  The polypill in the primary prevention of cardiovascular disease: cost-effectiveness in the Dutch population.

Authors:  Paul F van Gils; Eelco A B Over; Heleen H Hamberg-van Reenen; G Ardine de Wit; Matthijs van den Berg; Albertine J Schuit; Peter M Engelfriet
Journal:  BMJ Open       Date:  2011-12-21       Impact factor: 2.692

3.  Recalibration of the SCORE risk chart for the Russian population.

Authors:  Dmitri A Jdanov; Alexander D Deev; Domantas Jasilionis; Svetlana A Shalnova; Maria A Shkolnikova; Vladimir M Shkolnikov
Journal:  Eur J Epidemiol       Date:  2014-09-02       Impact factor: 8.082

4.  Tailoring the implementation of new biomarkers based on their added predictive value in subgroups of individuals.

Authors:  A van Giessen; K G M Moons; G A de Wit; W M M Verschuren; J M A Boer; H Koffijberg
Journal:  PLoS One       Date:  2015-01-26       Impact factor: 3.240

5.  A six question screen to facilitate primary cardiovascular disease prevention.

Authors:  Niels V van der Hoeven; Maurice A J Niessen; Erik S G Stroes; Lex Burdorf; Roderik A Kraaijenhagen; Bert-Jan H van den Born
Journal:  BMC Cardiovasc Disord       Date:  2015-10-30       Impact factor: 2.298

6.  Impact of effectiveness information format on patient choice of therapy and satisfaction with decisions about chronic disease medication: the "Influence of intervention Methodologies on Patient Choice of Therapy (IMPACT)" cluster-randomised trial in general practice.

Authors:  Charlotte Gry Harmsen; Dorte Ejg Jarbøl; Jørgen Nexøe; Henrik Støvring; Dorte Gyrd-Hansen; Jesper Bo Nielsen; Adrian Edwards; Ivar Sønbø Kristiansen
Journal:  BMC Health Serv Res       Date:  2013-02-25       Impact factor: 2.655

7.  Personalized prediction of lifetime benefits with statin therapy for asymptomatic individuals: a modeling study.

Authors:  Bart S Ferket; Bob J H van Kempen; Jan Heeringa; Sandra Spronk; Kirsten E Fleischmann; Rogier L G Nijhuis; Albert Hofman; Ewout W Steyerberg; M G Myriam Hunink
Journal:  PLoS Med       Date:  2012-12-27       Impact factor: 11.069

8.  Which patient and treatment factors are related to successful cardiovascular risk score reduction in general practice? Results from a randomized controlled trial.

Authors:  Ans H Tiessen; Andries J Smit; Jan Broer; Klaas H Groenier; Klaas Van der Meer
Journal:  BMC Fam Pract       Date:  2013-08-23       Impact factor: 2.497

9.  SCORE performance in Central and Eastern Europe and former Soviet Union: MONICA and HAPIEE results.

Authors:  Olga Vikhireva; Andrzej Pajak; Grazyna Broda; Sofia Malyutina; Abdonas Tamosiunas; Ruzena Kubinova; Galina Simonova; Zdena Skodova; Martin Bobak; Hynek Pikhart
Journal:  Eur Heart J       Date:  2013-06-20       Impact factor: 29.983

10.  Predicting 10-Year Risk of Fatal Cardiovascular Disease in Germany: An Update Based on the SCORE-Deutschland Risk Charts.

Authors:  Viktoria Rücker; Ulrich Keil; Anthony P Fitzgerald; Uwe Malzahn; Christof Prugger; Georg Ertl; Peter U Heuschmann; Hannelore Neuhauser
Journal:  PLoS One       Date:  2016-09-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.